scholarly journals A comparative study of efficacy of tadalafil and alfuzosin regimens in patients of benign prostate hyperplasia

2018 ◽  
Vol 7 (6) ◽  
pp. 1123
Author(s):  
Supratik Das ◽  
Harjinder Singh ◽  
Vijay Kumar ◽  
Jasbir Singh
Keyword(s):  
Urine Analysis ◽  
Benign Prostate Hyperplasia ◽  
Digital Rectal Examination ◽  
Prostate Hyperplasia ◽  
Randomised Study ◽  
Non Invasive ◽  
Urinary Tract Symptoms ◽  
The Mean ◽  
Benign Prostate

Background: Aim of the study was to compare efficacy of Tadalafil and Alfuzosin regimens in patients of Benign Prostate Hyperplasia.Methods: It was a comparative, prospective, observational, non-invasive, parallel and randomised study conducted at the Outpatient Department of Urology, Rajindra Hospital, Patiala. 60 patients diagnosed with Benign Prostate Hyperplasia along with Lower Urinary Tract Symptoms, out which, 30 patients, consuming Tadalafil and 30 patients consuming Alfuzosin were considered. History regarding the concerned disease and the compliance of treatment was taken. Symptom scores were assessed with the help of International Prostate Symptom Score, Quality of Lifestyle Score and Erectile Dysfunction Score. Physical examination consisting of Focused Neurological Examination along with Digital Rectal Examination were conducted. Parameters like Renal Function Test, Urine analysis, Ultrasound of Prostate and uroflowmetry were also considered.Results: The mean age selected for study was 64 years for Tadalafil and Alfuzosin group. The mean level of IPS Score, Qol Score and ED Score at the first day of inclusion of patients were 23.96±4.49, 4±0.78, and 25.33±4.02 respectively for Tadalafil group and regarding Alfuzosin group they were 25.23±4.84, 3.56±0.81, and 26.1±4.04 respectively. Follow ups were conducted at 15 days, 1 month and 3 months for both the groups which were found to be statistically significant after 3 months and Alfuzosin showed a favourable result.Conclusions: Alfuzosin 10mg given at daily dose was found to have higher efficacy than Tadalafil (5mg).

scholarly journals EKSPRESI Hsa-miR-22-3p PADA URIN PASIEN BENIGN PROSTATE HYPERPLASIA (BPH) SEBAGAI BIOMARKER NON INVASIF

2021 ◽  
Vol 20 (1) ◽  
pp. 93-102
Author(s):  
Angga Dwi Prasetyo
Keyword(s):  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Urine Samples ◽  
Transurethral Resection Of Prostate ◽  
Cross Sectional ◽  
Prostate Hyperplasia ◽  
Non Invasive ◽  
Prostate Diseases ◽  
Benign Prostate

Benign Prostate Hyperplasia (BPH) is one of prostate diseases with highest prevalence rates men in the world. Benign Prostate Hyperplasia are caused by many factors, such as disorders of androgen receptors, mutations genes, age, epigenetics and environment. Detection BPH in the form of Prostate Specific Antigen (PSA), Transurethral Resection Of Prostate (TURP) and Digital Rectal Examination (DRE) which is invasive in the patient. MicroRNAs in urine eksosomes can be used to detect BPH with non-invasive to patients. This study aims to determine the potential expression of Hsa-miR-22-3p in eksosomal urine samples of BPH as a non-invasive biomarker. This was an observational cross sectional analytic study. Urine samples were obtained from dr. Sardjito Yogyakarta and dr. Soeradji Tirtonegoro hospital. Furthermore, eksosomes isolation, RNA isolation, cDNA synthesis and quantification with qRT-PCR. Based on the results, it is known that Hsa-miR-22-3p decreased expression as much as 29.54 times in BPH, there were significant differences between samples of BPH and normal samples (P = 0.001). Thus Hsa-miR-22-3p has potential as a biomarker in Benign Prostate Hyperplasia. 

Sign in / Sign up

Export Citation Format

Share Document